Pacific Biosciences of California PACB Debt-to-equity

Debt-to-equity at other companies

IlluminaILMN

0.7×-0.2×

Quanterix CorporationQTRX

0.1×0.0×

RevvityRVTY

0.5×+0.1×

Twist Bioscience CorporationTWST

0.2×0.0×

Agilent TechnologiesA

0.5×-0.1×

Rapid Micro BiosystemsRPID

1.3×+1.2×

FAQ

What is Pacific Biosciences of California's debt-to-equity?

Pacific Biosciences of California (PACB) reported debt-to-equity of 25.1× in Q1 2026.

How has Pacific Biosciences of California's debt-to-equity changed year-over-year?

Pacific Biosciences of California's debt-to-equity increased by 4240.9% year-over-year, from 0.6× to 25.1×.

What is the long-term trend for Pacific Biosciences of California's debt-to-equity?

Over 5 years (2020 to 2025), Pacific Biosciences of California's debt-to-equity has grown at a 143.3% compound annual growth rate (CAGR), from 0.1× to 10.7×.

What does debt-to-equity mean?

Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.